Jacob Donoghue
CEO & Co-Founder,
Beacon Biosignals
United States
Jake translates scientific innovation into clinical interventions. He recently completed his MD from Harvard Medical School and PhD in neuroscience from MIT, leading research into the effects of neuroactive compounds on brain network activity. His published works span epilepsy, cognition and machine learning methods for quantifying pharmacological effects on neural activity.
Sessions


